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Background: Vaccination against Human Papillomavirus (HPV) is recommended for adolescent young women prior to
sexual debut to reduce cervical cancer related mortality and morbidity. Understanding factors affecting decision-making
of HPV vaccination of young women is important so that effective interventions can be developed which address
barriers to uptake in population groups less likely to receive the HPV vaccine.
Methods: We undertook a qualitative systematic review and evidence synthesis to examine decision-making relating
to the HPV vaccination of young women in high-income countries. A comprehensive search of databases from
inception to March 2012 was undertaken to identify eligible studies reporting the perspectives of key stakeholders
including policy makers, professionals involved in programme, parents, and young women. Factors affecting uptake
of the vaccine were examined at different levels of the socio-ecological model (policy, community, organisational,
interpersonal and intrapersonal).
Results: Forty-one studies were included. Whether young women receive the HPV vaccine is strongly governed by the
decisions of policy makers, healthcare professionals, and parents. These decisions are shaped by: financial
considerations; social norms and values relating to sexual activity, and; trust in vaccination programmes and healthcare
providers. Financial constraints may be overcome through universal healthcare systems offering the HPV vaccine free at
the point of delivery. In the healthcare setting, judgements by healthcare professionals about whether to recommend
the vaccine may restrict a young woman’s access to the vaccine irrespective of her own beliefs and preferences.
Parents may decide not to allow their daughters to be vaccinated, based on cultural or religious perceptions about
sexual activity.
Conclusions: Barriers to the uptake of the HPV vaccine have implications for young women’s future sexual, physical and
reproductive health. Interventions to address barriers to uptake of the vaccine should target appropriate, and multiple,
levels of the socio-ecological model. Issues of trust require clear, accessible, and sometimes culturally appropriate,
information about the HPV vaccination programme. Although young women are central to the HPV vaccination
programme, their views are underrepresented in the qualitative literature. Future research should consider young
women’s perceptions of, and involvement in, consent and decision-making.
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The World Health Organisation (WHO) recommends a
three dose vaccination schedule for females aged between
nine and 13 years [1] although schedules vary by country.
Vaccination prior to sexual debut is advised to ensure pro-
tection before exposure to the target HPV types. In 2007,
Australia became the first country to establish a national,
school-based HPV vaccination programme offering HPV
vaccine free at the point of delivery to young women aged
between 12 and 13 years. Other countries, including the
United Kingdom (UK), Sweden and Canada, have since
introduced universal school-based HPV vaccination pro-
grammes within their national immunisation schedules. In
the United States of America (USA), where insurance is
the predominant model of care, the vaccine is provided
through the healthcare setting; young women who are
Medicaid eligible, uninsured or underinsured are eligible
for vaccination free of charge [2].
The United Nations Convention on the Rights of the
Child recognised the rights for all children and young
people to participate in decision-making processes which
involve them [3]. The legal framework for consent to
vaccinate young women against HPV differs between
countries. In Australia, parental consent is required and
young women cannot be vaccinated without it. In con-
trast, in Canada, UK, USA and Sweden, young women
are legally able to override parental decisions if they are
considered mature enough to make, and understand the
consequences of, the decision.
A systematic review and meta-analysis, comprising
predominantly studies related to HPV vaccination pro-
grammes delivered in healthcare settings, indicated lower
initiation by ethnic group and in young women without
healthcare coverage insurance. No strong evidence for dif-
ferences by parental education or family income variables
were shown [4]. In the UK, where the HPV vaccination is
provided primarily through the universal schooling sys-
tem, inequalities in uptake by social deprivation have not
been demonstrated [5-7]. However, lower uptake for mi-
nority ethnic young women are apparent [6-8]. This is of
concern as women from minority ethnic population
groups may be at increased risk of developing cervical
cancer [9], but less likely to attend for cervical cancer
screening [10,11].
High coverage of HPV vaccination programmes has the
potential to reduce substantially cervical cancer incidence
and mortality [12-14]. However, health inequalities may be
increased if uptake remains lower amongst certain popula-
tion groups. An increasing number of qualitative studies
have been undertaken to provide insight into the views
and perspectives from various population groups in rela-
tion to HPV vaccination of young women. By systemati-
cally retrieving, pooling and comparing the available data,
qualitative synthesis can provide a better understanding ofthe reasons why some young women do not receive the
HPV vaccine. This is important so that interventions can
be developed to successfully promote uptake and address
inequalities [15].
In order to provide understanding of factors affecting
uptake of the HPV vaccination programme, we focused
on facilitators and barriers to decision-making by key
stakeholders. Additionally, explanations for lower up-
take by young women from minority ethnic groups were
sought.
Methods
A protocol for this qualitative systematic review and evi-
dence synthesis was not registered with a database. How-
ever, systematic review methods were followed to identify
all the relevant qualitative literature pertaining to the re-
search question and are described below.
Search strategy
A comprehensive search strategy for Embase was devel-
oped to ensure that all relevant literature was captured. A
combination of text words and the following indexing
terms (MeSH) was used: “papillomavirus”, “wart virus”,
“vaccination”, “immunization”, “immunization programs”,
“wart virus vaccines”, “qualitative”, “interviews” and “focus
groups” (Additional file 1). The search strategy was subse-
quently modified for other databases. The following data-
bases were searched from inception to 9th March 2012:
CINAHL; Embase; Medline; PsycINFO, and; ISI Web of
Science and ISI Proceedings. All abstracts were saved
using Endnote ×3 reference manager software.
Inclusion and exclusion criteria
Studies were eligible if qualitative research methods (in-
terviews, focus groups, observations) or open-ended
questions in questionnaires were used to explore views
and behaviours related to decision-making of HPV vac-
cination of young women. The populations of interest
were: young women; their parents and/or primary care
givers; healthcare professionals involved in the delivery
of the programme, and; other relevant stakeholders such
as policy makers, community leaders, and teachers.
Young women were defined as adolescent girls aged bet-
ween nine and 18 years. Studies which included the
views of women over the age of 18 years were included
if the views of young women were reported separately.
No restriction was imposed by publication date in order
to capture views of the HPV vaccine before its general
availability (which might influence future delivery or up-
take) as well as existing HPV vaccination programmes.
Studies not published in English were excluded. Con-
ference abstracts, editorials, letters and books were in-
cluded only if they presented original qualitative data.
Primary studies with adults were excluded if views about
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the results. Questionnaire studies reporting only closed
questions were excluded. For this paper, with a focus on
examining factors affecting decision-making in high-
income countries, studies were categorised as high-
income using the World Bank classifications [16].
Study selection
Two reviewers (HF and SA) independently assessed the
titles and abstracts from the literature searches and the
relevance of studies retrieved as full text. Disagreements
were resolved by discussion. The reference lists and
bibliographies from relevant studies and reviews were
hand-searched by one reviewer (HF) for additional pri-
mary studies not retrieved by the electronic search.
Quality assessment
Currently, there is no consensus regarding the assess-
ment of the quality of qualitative research and subse-
quent exclusion from systematic reviews [17]. For this
systematic review and evidence synthesis, each primary
study was appraised using the Critical Appraisal Skills
Programme criteria for evaluating qualitative research
[18]. Studies were not automatically excluded on the
basis of overall ‘low quality’ if they contributed relevant
qualitative information. However, the methodology and
results of one study was presented in such a way that
the findings were considered unreliable and this was ex-
cluded [19].
Data extraction
Data pertaining to the methodology and context, inclu-
ding study and participant characteristics of each pri-
mary study, were extracted and entered into an excel
spread sheet by one reviewer (HF).
Thematic synthesis
Several methodologies for the synthesis of qualitative re-
search exist [20].To analysis the data, the methodology
was based on the methods of thematic synthesis reported
by Thomas and Harden and using the Framework
methods of qualitative data management [21-23]. These
methods suit studies with a priori aims and objectives de-
signed to directly inform policy and practice. The overall
purpose of the synthesis was to ‘pool’ the results from
individual primary studies by initially separating the fin-
dings, interpreting and then combining them through the
identification of key themes across the studies [24].
Thematic synthesis was undertaken by one reviewer
(HF) with discussions held with the second reviewer (SA)
as analysis progressed. Elements of the text reported in the
‘results’ section of each primary study represented the
basic units of the review. The text from each primary study
was extracted verbatim and entered into a spreadsheet.The data was ‘charted’ into the matrix for studies relating
to: young women, their parents/carers, and professionals.
Familiarisation with the dataset included reading and re-
reading the textual data in these primary charts. Sections
of text were coded, with multiple codes being allocated
where appropriate. The primary charts were retained and
revisited as required, but streamlined versions were pro-
duced as the process of summarising and synthesising the
data progressed. In these subsequent charts, key terms
and phrases were retained while repetition within studies
and extraneous text were removed. During this process,
differences or similarities were identified within emerging
themes.
The socio-ecological model
During analysis the findings were considered in relation
to the socio-ecological model [25] which considers that
behaviour is shaped by a complex interaction between
factors operating at the following levels: (i) public policy;
(ii) community; (iii) organisational; (iv) interpersonal,
and; (v) intrapersonal. We used the socio-ecological
model to provide a framework for understanding how
decisions of stakeholders at different levels of the model




Of 1,104 records initially identified through the database
searches, 490 abstracts were reviewed and 130 full text
articles assessed for eligibility of which 41 were eligible
for inclusion (Figure 1).
Study and participant characteristics
Most studies were undertaken in the USA (n = 24, 58.5%)
and the UK (9, 22.0%), with a further three studies in
Australia, two in Sweden, two in Hong Kong and one in
Canada. Study settings included healthcare (21, 51.2%),
community (12, 29.3%), schools (6, 14.6%), government (1,
2.4%) and a combination of settings (1, 2.4%). Most studies
were considered to be at moderate risk of bias (n = 20,
48.8%), followed by low risk (12, 29.3%), and high risk (9,
22.0%) (Table 1). Study participants included parents (16
studies, 39.0%), healthcare professionals (12, 29.3%), and
young women (6, 14.6%), or a combination of participants
(7, 17.1%). Reported sample size ranged from 10 to 522.
More studies were undertaken post-licensure (25, 61.0%)
of the HPV vaccine rather than pre-licensure (n = 16,
39.0%) (Table 2).
The socio-ecological model and cross cutting themes
The data suggest that young women’s access to the HPV
vaccine is influenced by the overall policy context and
decisions of key stakeholders operating at different levels
88 full-text studies excluded for 
being:
- not qualitative research 
methods (n=25)
- conference proceedings or
dissertation (n=11)
- full report obtained elsewhere
(n=8)
- not population of interest (n=6)
- review article (n=6)
- no specific mention of HPV
programme (n=4)
- not published in English (n=2)
- not high-income country (n=18)
- did not report decision-making 
in results (n=8)
1 full-text study excluded that was 
identified as methodically flawed 
during quality assessment
1,104 records identified 
through database searching
361 records excluded for being:
- not qualitative research 
methods (n=217)
- not in relation to HPV vaccine 
(n=82)
- not population group of interest 
(n=34)
- not active research participants 
(n=5)
- conference proceedings (n=23)
130 full-text studies 
assessed for eligibility
490 records screened after duplicates 
removed
8 additional records identified 
by other sources
41 relevant studies 
identified
Figure 1 Flow diagram of study selection procedure.
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fessionals and teachers, parents and the young women
themselves (Table 3). Five cross cutting themes were also
identified that related to decision-making: mandate,
finance, sexual mores, trust, and consent. These are dis-
cussed below from the perspectives of the different
stakeholders involved. Although these themes are rele-
vant to all young women, it became clear that some had
particular pertinence for young women from minority
ethnic groups and may help to explain identified dif-
ferences in uptake. This is considered further in the
discussion.
Mandate
In the USA, routine HPV vaccination was recommended
for girls between ages 11 and 12 by the national Advisory
Committee on Immunisation Practices (ACIP) in 2006
[26]. However, whether a vaccine should be mandatory for
school attendance is predominantly decided by state legis-
latures and is subject to debate. At the time the studies
were undertaken, policy makers in the USA were not clearthat a school-based mandate for the HPV vaccine was ap-
propriate. Lack of transmissibility in the school-setting
was felt to undermine the need to a mandate: “I can com-
pletely support it in certain kinds of infectious diseases that
are a threat in terms of morbidity and mortality, and are
easily transmitted within a classroom, for example, but
HPV is not one of the things” [Policy maker, USA] [27].
Policy makers also considered likely opposition from ‘anti-
vaccination’ groups [27,28].
The mode of transmission of HPV was also considered
by healthcare professionals [29,30]: “The only mandates we
currently have for vaccines in our country are for infectious
diseases spread in a school setting. It would not be a school
issue or a public health issue, but more of an individual
issue” [Paediatrician, USA] [30]. However, school-entry
mandates were also perceived by healthcare professionals
to be advantageous in creating universal access to HPV
vaccine: “Realistically, that’s how you’re going to get those
patients who fall under the system to get vaccinated”
[Paediatrician, USA] [30]. Further, the absence of
school-entry mandates was thought to diminish parental
Table 1 Study characteristics of primary studies













2011 USA To describe parents’
knowledge, attitudes, and
decision-making with regard









Focus groups Convenience Grounded theory Medium
Bair R,
et al. [51]
2008 USA To describe Latina mothers’
acceptance of the human
papillomavirus vaccine for










Interviews Convenience Thematic analysis Medium
Brabin L,
et al. [53]
2007 UK To investigate parents’ views
on making available HPV
vaccination to adolescent
minors at sexual health clinics
without parental consent






Convenience Thematic analysis Low
Brown E,
et al. [55]
2009 UK To explore GPs’ and practice




programme, with a focus on
































2011 Hong Kong To explore the experience
and attitudes of physicians in
clinics, and to facilitate













2010 USA To identify the factors that
were most influential in
determining how states



























Table 1 Study characteristics of primary studies (Continued)
Constantine N,
et al. [50]


















2010 Australia To explore experiences,
knowledge, attitudes,
decision-making processes,
and contextual factors related
to consent to vaccination
and vaccination completion
















2010 Australia To explore experiences,
knowledge, attitudes,
decision-making processes,
and contextual factors related
to consent to vaccination
and vaccination completion
















2009 USA To compare the reasons why


















2009 USA To address HPV vaccine
knowledge and beliefs




2008 Focus groups and
interviews
Convenience Thematic analysis High
D’Souza C,
et al. [37]
2011 Australia To examine the development














2007 USA To collect data on the
general public’s knowledge,
attitudes and beliefs
regarding HPV and a












2011 UK To explore attitudes to
human papillomavirus
vaccination and reasons for
accepting or declining the






























Table 1 Study characteristics of primary studies (Continued)
Gottvall M,
et al. [39]
To investigate school nurses’
perceptions of HPV
immunisation, and their task
of administering the vaccine











2011 UK To offer insights into
adolescent girls’
understanding of HPV, its link
















2011 UK To offer insights from school
nurses’ perspectives and









































2005 Focus groups and
interviews
Not described Grounded theory Medium
Hutson S,
et al. [60]
2011 USA To investigate
communication and cultural
issues that may influence
vaccine uptake among
southern Appalachian
women and explore their








Convenience Content analysis Medium
Javanbakht M,
et al. [28]




adolescent girls in a
community with high cervical
cancer rates











2007 USA To describe the range of
pediatricians’ attitudes about
human papillomavirus
vaccines and to explore
factors influencing their
intention to recommend HPV
vaccines
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Katz M,
et al. [34]






Summer 2007 Focus groups and
interviews
Convenience Thematic analysis Medium
Kwan C,
et al. [32]
















Not described Focus groups Purposive Thematic analysis Low
Marlow L,
et al. [45]
2009 UK To explore attitudes to HPV
vaccination among black and



























Interviews Purposive Content analysis Medium
Mishra A,
et al. [56]
2012 Canada To illustrate the clinical,
political and practical
complexities of introducing






Interviews Convenience Thematic analysis High
Olshen E,
et al. [46]













Convenience Content analysis Medium
Oscarsson M,
et al. [38]
2011 Sweden To explore youth clinic
midwives role in cervical
cancer prevention and their







Interviews Convenience Content analysis Medium
Perkins R,
et al. [29]



















2010 USA To explore low-income mi-
nority parents’ attitudes, in-
tentions, and actions with
regard to human papillomavi-

















2012 USA To conduct a qualitative
examination of free text
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2009 UK To seek the views of school
nurses on vaccinating girls







July 2008 Interviews Convenience Thematic analysis Low
Shafer A,
et al. [63]
2011 USA To develop HPV vaccine
messages for a campaign
targeting racially diverse
mothers of nonvaccinated 11










2007 USA To better understand the
implications for counselling
about cervical cancer
prevention by primary care




July 2004 to May
2005
Focus groups Purposive Thematic analysis Medium
Teitelman A,
et al. [33]
2011 USA To identify common beliefs
about HPV vaccine initiation
and describe the relationship
between attitudes, norms,
perceived control, and









Not described Focus groups Convenience Content analysis High
Tissot A,
et al. [26]
2007 USA To examine pediatricians’
views about key issues
related to HPV vaccine
delivery and identify their
strategies for effective
vaccine delivery












2008 USA To describe Alaska Native
parents’ knowledge of and
attitudes towards cervical
cancer, the human








Focus groups Convenience Not described High
Waller J,
et al. [52]
2006 UK To investigate responses to
information about the HPV
vaccine among mothers of













2010 UK To explore knowledge about
human papillomavirus and
attitudes towards HPV
vaccination among girls who
were part of the ‘catch-up’
vaccination programme
One further education



























Table 2 Participant characteristics of primary studies











Socioeconomic Race/ethnicity Sex Religion
Allen J,
et al. [61]
2011 Parents of daughters









Female: 72% Not described
Bair R,
et al. [51]
2008 Latina mothers of








Latina: 100% Female: 100% Not described
Brabin L,
et al. [53]
2007 Parents of Year 7 (11






















17 N/A Pre-licensure General practices:
one deprived area,
two affluent area
Not described Not described Not described
Bynum S,
et al. [31]















12 N/A Post-licensure Not described Not described Not described Not described
Colgrove J,
et al. [23]
2010 Key stakeholders Not
described
73 N/A Post-licensure Not described Not described Not described Not described
Constantine N,
et al. [50]























































Not described Female: 100% Not described
Do H,
et al. [36]
2009 Key informants and
parents of at least







































Vaccinated Post-licensure Not described Australian: 80% Female: 100% Not described
Friedman A,
et al. [62]
2007 Adults aged 25 to 45 Range: 25 to
45




Female: 50% Not described
Gordon D,
et al. [44]






20 Mixed Post-licensure Degree education:
65%
Not described Female: 100% Jewish: 100%
Gottvall M,
et al. [39]
2011 School nurses Range: 35 to
60
30 N/A Pre-licensure Not described Not described Not described Not described
Hilton S,
et al. [58]




87 Mixed Post-licensure High and low
areas of
deprivation
Not described Female: 100% Not described
Hilton S,
et al. [42]
2011 School nurses Not
described


























35 N/A Pre-licensure Not described Not described Not described Not described
Hutson S,
et al. [60]




39 Mixed Post-licensure Not described Appalachian
community







21 N/A Post-licensure Not described Not described Not described Not described
Kahn J,
et al. [40]
2007 Paediatricians Range: 30 to
78
31 N/A Pre-licensure Not described White: 58%, Black:
29%, Latino: 13%








114 N/A Pre-licensure Various White:106, Non-
Hispanic: 111
Not described Not described
Kwan C,
et al. [32]
2008 Girls aged 13 to 20 Range: 13 to
20
64 N/A Pre-licensure Parental
education:
Secondary 64%
Chinese: 100% Female: 100% Not described
Marlow L,
et al. [45]
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Mays R,
et al. [47]
2004 Parents with children
aged 8 to 17
Range: 26 to
55
34 N/A Pre-licensure College: 50% Not described Female: 85% Not described
Mishra A,
et al. [56]




15 N/A Post-licensure Not described Not described Not described Not described
Olshen E,
et al. [46]










Female: 88% Not described
Oscarsson M,
et al. [38]
2011 Midwives Range: 38 to
62
13 N/A Post-licensure Not described Not described Not described Not described
Perkins R,
et al. [29]
2010 Parents of vaccine


















2010 Low income parents Range: 31 to
60
















112 N/A Post-licensure Not described Not described Not described Not described
Shafer A,
et al. [63]
2011 Female caregivers of
11 to 12 year old girls
Not
described




Female: 100% Not described
Stretch R,
et al. [57]
2009 School nurses Not
described





37 N/A Pre-licensure Not described Not described Female: 86% Not described
Teitelman A,
et al. [33]
2011 Girls aged 13 to 26 Range: 13 to
26
34 Mixed Post-licensure Low income
population
Black: 74% Female: 100% Not described
Tissot A,
et al. [26]
2007 Paediatricians Mean: 46.9 31 N/A Pre-licensure Not described White: 58%, Black:
29%, Asian
American: 7%





























80 Mixed Post-licensure Not described Alaskan natives Female: 81% Not described
Waller J,
et al. [52]




24 N/A Pre-licensure Degree level: 50%, Not described Female: 100% Not described
Williams K,
et al. [54]
2010 Girls aged 17 to 18 Range: 17 to
18
10 Mixed Post-licensure Not described White British: 80%;
British Asian: 20%




















Table 3 The socio-ecological model: factors influencing young women’s uptake of the HPV vaccine in high-income
countries
Level Key issues Cross cutting themes
Policy Vaccine availability, cost and delivery Mandate Finance Sexual mores Trust Consent
Community Social norms and values
Organisational Healthcare professional recommendation and provision
Interpersonal Parental decision-making and consent
Intrapersonal Young women’s characteristics and consent
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http://www.biomedcentral.com/1471-2458/14/700perceptions of the importance of the vaccine [29,31,32]:
“Some patients, again, come in saying, ‘We don’t want
that because’ friends of them are telling them it’s not
really mandatory or it’s not really gonna affect ‘em”
[Staff person, USA] [32].
Some parents shared the concerns of policy makers and
healthcare professionals, in relation mandating a vaccine
for a disease that was not transmissible in the school set-
ting [33]. However, other parents supported a school-
entry mandate to ensure that all young women could
receive benefits of the vaccine: “[If HPV vaccine were man-
dated, I would feel] grateful because we parents want the
best for our children, and thank God science has disco-
vered new medicines to prevent diseases” [Latina mother,
USA] [33].
Finance
In countries without universal healthcare coverage, the
costs of the vaccine were identified as an important bar-
rier to provision of, and access to, the HPV vaccine. In
the USA, policy makers considered that public bodies
and private insurance companies had been responsive in
meeting HPV vaccine associated costs [27]. However,
healthcare providers noted a financial burden that in-
fluenced whether they provided vaccines to their popula-
tion: “There is no way vaccines are cost-effective for us. It
costs us an incredible amount of money in terms of time.
Because the time we spend, the time the nurses spend…
we’re not even close to being reimbursed for the amount
of time we spend on vaccines” [Practitioner, USA] [29].
Without universal healthcare coverage, the financial costs
of the HPV vaccine appear likely to prevent uptake by the
typically most disadvantaged families. Healthcare profes-
sionals indicated the high price [34], lack of healthcare in-
surance [30,32], and inadequate insurance reimbursement
[29,31] were important barriers to provision and uptake:
“The only reason myself and my colleagues [sic] not able to
offer HPV vaccine to our patients is lack of reimbursement
[by insurance companies]” [Physician, USA] [31].
Financial barriers were also mentioned by families and
community members in these settings [35-40]: “My
gynecologist offers the HPV vaccine but you have to pay
$135 up front and it is three shots, so you pay $135 a piece
for each shot and insurance does not reimburse you orcover it” [Participant, USA] [38];“Insurance don’t pay for
everything [provides partial payment] and then a lot of
times insurance doesn’t cover everything [some services not
covered at all]” [Young woman USA] [37]. Where the vac-
cine was not available free at the point of delivery, young
women were also aware that the high cost could render
the HPV vaccine unaffordable [35-37]:“Where will I get
the money for it [HPV vaccine]? At this price, my family
could not support me either” [Young woman, Hong Kong]
[36]. This contrasts with the ‘catch up’ campaign in
Australia where the vaccine was provided free for a li-
mited time: “They were doing it for free, so mum was like,
‘You’d better go’ ” [Young woman, Australia] [41].
In Sweden, the HPV vaccine was made available in the
healthcare setting for young women aged 13 to 17 years
who paid for it. In these circumstances, healthcare profes-
sionals felt hindered in recommending the vaccination to
disadvantaged families: “It is difficult to bring up the ques-
tion of vaccination to youth if you can see they do not have
the money to pay for it, or the family can’t afford to buy
the vaccination for them as it is so expensive, it feels a little
unethical to take this up with young people” [Midwife,
Sweden] [42]. Offering the HPV vaccine free at the point
of delivery through a national school-based programme
was considered advantageous in terms ability to reach the
wider population: “If one thinks about the whole commu-
nity, then it is, of course, good, I think. So that everyone
has the opportunity… Even those who don’t have the
means, like those who have parents who wouldn’t pay”
[School nurse, Sweden] [43].
This important barrier to uptake was not evident in
studies where the vaccine was offered free at the point
of delivery.
Sexual mores
Social norms and values, particularly those relating to sex-
ual debut and behaviour, shaped the views and actions of
healthcare professionals, parents and young women in re-
lation to the HPV vaccine.
This influenced the decisions of healthcare profes-
sionals about whether to recommend the HPV vaccine
in healthcare settings [29-31,44,45]. Some young women
were thought to be in greater need of protection: “Well,
you know, we try not to be judgmental, but we know
Ferrer et al. BMC Public Health 2014, 14:700 Page 15 of 22
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sexual activity with multiple partners is more common,
more prevalent…we treat them frequently for various
STDs” [Pediatrician, USA] [30]. In other cases, health-
care professionals appeared reluctant to discuss sexually
related information: “There are just lots of docs who
don’t like to talk about sex with their patients. That will
be a huge barrier” [Pediatrician, USA] [44]. This was
especially pertinent for families with strong faith beliefs
who were “culturally more modest in terms of how they
approach sexual issues…you’d see that in conservative
Christian cultures as well” [Pediatrician, USA] [30].
In this context, healthcare professionals noted that
parental perceptions of adolescent sexual behaviour in-
fluenced parental decision-making: “They don’t want their
child to start talking about sex… or their parents don’t
really know how to relay that information to them”
[Healthcare provider, USA] [32]. In one study, it was sug-
gested parents would be receptive to the HPV vaccine: “If
we brought up the fact that there is a way of preventing
even one out of four or five STDs, our parents are going to
be banging on the door to get it at 11, 12, 13. I’m not wor-
ried about the discussion with our group” [Clinician, USA]
[45]. More commonly, resistance was anticipated due to
connections with sexual activity [29,31,32,44,45]: “HPV
has so many other implications for parents… it’s one they
fight you on…because you’re suggesting that their child is
or will be sexually active soon, and they don’t want to hear
that” [Clinician, USA] [45]. In three studies, healthcare
professionals reported that parents delayed vaccination of
their daughter on this basis [31,32,44].
In contrast to delivery in healthcare settings, there was
no evidence that perceptions of need by healthcare profes-
sionals affected their decisions to offer the HPV vaccine in
school-based HPV vaccination programmes. However,
there were concerns about the potential to adversely affect
young women’s sexual health if young women assumed
greater protection than is the case [42,43]: “I haven’t heard
it myself, but someone else heard from a girl that had been
vaccinated that she was vaccinated against all sexually
transmitted disease” [Midwife, Sweden] [42]. In addition,
some parental resistance to the HPV vaccine due to con-
nections with sexual behaviour were reported [46,47]: “We
had quite a few phone calls, predominantly from [Asian]
mothers, they were very concerned that by them okaying
the needle, that was giving the daughters the green light to
go and become sexually active” [Teacher, Australia] [47].
Irrespective of delivery setting, the need for cultural sen-
sitivity was highlighted: “Cultures in which a girl must be
a virgin at marriage, and so on. Clearly, it becomes very
difficult to talk about multiple partners then. And one can-
not… it’s like offensive, I think” [School nurse, Sweden]
[43]. This appeared to be an especially pertinent issue for
parents with strong faith beliefs for whom sexual contactoutside of marriage and multiple sexual partners were per-
ceived to occur infrequently [47-49]: “Coming from a
Muslim background… We don’t have sex before marriage
for example, so your first experience of these things are
when you’re married and you stay in a relationship… be-
cause of that reason I’d probably say no, I wouldn’t bother
with it with my two girls” [Asian Muslim mother, UK]
[49]. However, other parents recognised changing cultural
norms and values, suggesting that their belief systems may
differ to that of their daughter [47,48]: “I went to the same
school and I had a religious upbringing but a lot of my
close friends who I grew up with are actually not religious
now and they are living a different lifestyle than I am…
my daughter may not grow up to live the way I do” [Jewish
mother, UK] [48].
The recommended age for vaccination was a concern
for parents. Those who acknowledged that young women
could be sexually active during adolescence appeared
more accepting of the HPV vaccine [39,50]: “I’d say pro-
bably [vaccination should happen at age] 11 or 12 defi-
nitely before they have sex. I think while they’re still in
early middle school. Once they get to the eighth grade and
high school they’re already into puberty and thinking. The
temptation is out there” [Parent, USA] [39]. Others valued
the protection afforded by HPV vaccination for situations
that could not be predicted, such as the unknown sexual
history of their partner [51-53]: “Even though we try to
practice that she’s only going to have sex with her husband,
I’m a little more realistic than that. Even if she only does
have sex with one man in her life, there’s no guarantee that
he hasn’t had other partners and that he might not be
a carrier” [Mother, USA] [53]. In line with healthcare
professionals’ accounts, some parents reported that they
would delay vaccination to an age more closely aligned
with their perception of sexual debut [45,48,54]: “I’ve
taught her not to have sexual relations at age 13, but at
16, it’s much more likely” [Mother, USA] [54].
Parents also raised concerns that the HPV vaccine could
invoke changes to sexual behaviour [38-40,51,54,55]:
“Because it would encourage my daughter to have sex and
I wouldn’t want that” [Mother, USA]. Parents raised con-
cerns that the HPV vaccine might encourage earlier sexual
debut, multiple sexual partners or complacency with
regards to safe sexual health practices [49,56]: “I think
maybe something like that you might take for granted and
not get screenings, because it still says to get screenings, but
you might just think, obviously a 12 or 13 year old might
be like oh, ‘I’ve had the vaccination now I’m fine’ and not
get screenings” [Mother, UK] [49]. Other parents dismissed
these viewpoints [52,54]: “I don’t think it’ll encourage my
daughter to go out and have sex. I don’t want her to have
sex now. She’s 14. I hope she has sex in the future and has
kids and lives a normal life, but I don’t think it will en-
courage her to go act irrationally” [Alaskan native father,
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tion appeared to increase acceptance of the HPV vaccine
[47-49,51,52,55,56]: “..I thought what a fantastic thing [the
vaccine], because I actually went to school with a girl who
can’t have children because she’s got cervical cancer, and
the reason she has cervical cancer is because she was very
promiscuous when she was at school with me” [Parent,
Australia] [47].
There was evidence of parental discomfort in discussing
sexually related information with their daughters
[47,56,57]: “So it’s easier to give it to younger children by
saying ‘It’s to prevent cancer’ than saying to them ‘you’re
having this because when you’re older you’re going to have
sex and get all these horrible diseases” [Mother, UK] [56].
Similarly, young women could also feel embarrassed
[47,58]: “We were just talking about it and she said ‘You
don’t need it yet, do you?’ and I was like ‘of course not
Mum’ and she was like ‘oh well, then we might just wait
then’ - and I think I said - …’ ‘well does that mean I have
to tell you when I need it, are you going to assume I’m
sexually active?’ and she said ‘no, no.’ Well all I was saying
is, ‘I want to have it now, because I don’t want to tell you
when I need it’ - that is really awkward” [Young woman,
Australia] [47]. Others were anxious that vaccination
might be negatively associated with their sexual behaviour
[36-38]: “If my family knows what this [HPV vaccine] is for
and if I say I want it, they would think that I am fooling
around” [Young woman, Hong Kong] [36].
Trust
Issues of trust relate to the vaccine’s safety profile, the
motives of pharmaceutical companies and whether it
was recommended by a trusted source. The opinions
of healthcare professionals were generally favourable
towards the HPV vaccine to prevent cervical cancer
[30,34,43-45,59-62]: “Yes, definitely… It’s a very common
virus, it causes quite a lot of disease and it can cause
some very serious disease, in rare cases, but that can be
prevented by the vaccine” [General practitioner, UK]
[59]. However, there was evidence for uncertainty in re-
lation to the safety profile of the vaccine [31,43,44] and
that early vaccination may mean that protection would
not be maintained to the age of sexual debut [29,30,44].
Parental decision-making in favour of the vaccine was
motivated by protection against HPV acquisition or the de-
velopment of HPV-related conditions [33,50-52,54-56,63].
There was also evidence of implicit belief in vaccines over-
all, with views about childhood vaccination being trans-
ferred to the context of the HPV vaccine [33,48,49,55,56]:
“If there is a new vaccine to prevent a disease, we won’t op-
pose it because we are preventing a disease” [Immigrant
parent, USA] [39].
Despite generally positive perceptions to the HPV vac-
cine, parents expressed worries concerning side-effectsand safety [38,39,48,49,51,53,56,63,64]: “My first thought
was, I am sendin’ my ten-year old to this clinic to put dead
HPV cells in her. What if the HPV that they are shooting
in her body…what if it comes to life?” [African American,
mother, USA] [65]. Such fears may be balanced against
the benefits of protection from vaccination [48,49]: “I just
decided that it was more dangerous to get the diseases
than to take the slight risk that there might have been side
effects” [Jewish mother, UK] [48].
Healthcare professionals suggested that parents with
general ‘anti-vaccination’ beliefs were unlikely to make
positive HPV vaccine decisions [30,40,46]: “I have some
[parents] that don’t want any vaccination… those I would
not even broach the subject with” [Paediatrician, USA]
[30]. This was confirmed in studies reporting the views
of parents, but only appeared to reflect the views of a
minority [40,49,54]: “Because she is not vaccinated, we
use holistic medicine” [Mother, USA] [54]. In one study,
there was evidence that parental ‘anti-vaccination’ beliefs
could influence their daughter: “Well I don't get immuni-
zations. I’ve never had any. My dad believes in boosting
our own immune system, not getting help… That’s what I
see as the advantage of not getting [the vaccine]” [Young
woman, Australia] [47].
In the USA, parents appeared to be distrustful of
pharmaceutical companies and governments providing
the vaccine [52,53,64,66]: “They [government] may not be
telling the full story, which, of course, we found out about
syphilis, we found out about AIDS” [African-American
participant] [66]. However, endorsement from a go-
vernmental source counteracted these concerns for other
parents: “At least [with] the [Centers for Disease Control
and Prevention] you know they’ve got some validity behind
their name that gives some validity to the drug maker be-
cause most drug makers I think are just out there to make
a buck” [Mother, USA] [67].
In countries with school-based HPV vaccination pro-
grammes, offering the vaccine through a trusted source
appeared to reduce the burden of decision-making for
parents: “There may have been a covering information let-
ter from the school… I suspect I read it…but I guess I must
have somewhere made the decision when I saw that it was
being offered to the general population that the girls would
have it and I don’t think I did any further research at that
point” [Jewish mother, UK] [48]; “If it hadn’t come to
school it wouldn’t have crossed my mind to do it… It’s not
[a decision you make] on an individual basis, and that
[having it as school] makes you more comfortable” [Parent,
Australia] [47]. In one study, implicit trust in the health-
care system also appeared to influence young women’s
acceptance of the vaccine: “I think the people in charge,
like Government’s health people have decided the jag
[vaccine] is in our interest so I feel there’s no reason not to
get it” [Young woman, UK] [62].
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also reduce trust and prevent young women receiving
the HPV vaccine [47,68]: “They pump all sorts of things
into kids… Do they really know how it will affect them
later? I don’t trust the government. Why would they need
[the vaccination] when we didn’t get it? What aren’t they
telling us? My sister showed me some articles about there
being cancer in the vaccine” [Parent, Australia] [47].
Consent
Because of the target age for HPV vaccination, parental
consent is either essential or strongly preferred. A num-
ber of parents were worried that they could be excluded
from the decision-making process [38,65]. Other parents
appeared less engaged: “I didn’t realise how ill-informed
I am. You just sign off on all these forms…” [Parent,
Australia] [47].
Gaining consent in school-based HPV vaccination pro-
grammes, where the parent is unlikely to attend during
the vaccination procedure, presented difficulties that
were not raised in the healthcare-setting. Engaging some
parents with the consent process could be challenging
[46,47,69,70]: “They couldn’t be bothered to read the
form or fill it in, you know, motivate themselves enough
to do it, but they always wanted the child to have it [the
vaccine] as long as somebody bothered to knock on the
door and say, ‘just sign on the dotted line’. It was just
the process of the filling of the form in was just too much
effort” [School nurse, UK] [46]. Only one of 15 participa-
ting school nurses indicated willingness to vaccinate if a
parental consent form had not been returned [61].
Differing levels of commitment to pursue consent were
evident amongst the professionals involved [43,46,61]: “It’s
an offer. And it shouldn’t be our job to call and call again
and again and invite them. I think that it’s actually the
parent’s responsibility, together with the student [aged 12
to 13 years]” [School nurse, Sweden] [43]. Targeting these
parents with information, consent forms, and flexible
HPV vaccination appointments was suggested [46,61,71].
This might be considered the responsibility of healthcare
professionals or teaching staff at the school: “You just need
to circulate the information in different channels, like the
school newsletter and… Daily notices to remind them to
bring their [consent forms] back. I spoke at assembly, and
they had year group meetings where the information was
distributed and making sure the classes and teachers are
informed of what’s happening” [Teacher, Australia] [71].
In the UK, both primary care professionals and school
nurses raised concerns about whether the school-setting
was appropriate for assessing a young woman’s compe-
tence to receive the vaccine without parental consent
[59,61,69]: “If everybody is given 30 seconds to get in and
get out, you can’t reasonably expect a nurse to make a de-
cision in that time. Yes or no? They would have to makesome sort of later appointment to speak to the young per-
son and have a serious chat which in itself would then sin-
gle them out from, you know if there was a mass queue”
[School nurse, UK] [69]. There was reluctance to chal-
lenge parents who actively refused consent for the HPV
vaccine [46,61,69]: “I would feel very uncomfortable about
that because what we are trying to do is build up a rela-
tionship with parents here. I am asking parents to support
the college in terms of rules, regulations, etc., and here I
am then saying to parents, ‘Well in this case tough, what
you say really does not count.’ It puts us in a very awkward
position” [Head teacher, UK] [69].
One school nurse justified her willingness to vaccinate
in the face of parental refusal on the grounds of a clear
health benefit: “If I know this particular twelve year old
girl is a risk of contracting an illness for which there is
an injection that will prevent this illness then it is most
definitely in her interest to give it to her, even if her par-
ents don’t agree” [School nurse, UK] [69]. Primary care
professionals also acknowledged the difficulty of vacci-
nating without parental consent: “Actually she’s being
very responsible in coming, we want to encourage that. I
still would feel extremely uneasy with going ahead with
the immunisation although you begin to feel then that
you are going against the fact she is trying to do some-
thing very responsible” [General practitioner, UK] [59].
Irrespective of setting, the extent to which parents in-
volved their daughters in decision-making about the
HPV vaccine varied. Some parents reported making the
decision, whereas others gave their daughter the free-
dom to choose [48,49,52,53,64,65]: “I didn’t discuss it
with the girls, I merely told them of my decision after-
wards. I didn’t feel that they were in a position to make
a decision for themselves… they are relatively sheltered
and therefore it wouldn’t have been relevant to ask them
what they thought” [Jewish mother, UK] [48]; “I would
let the decision be up to her, but she should be informed.
The more informed she is, the better off she’ll be making
the decision, and she won’t feel forced by you, or anybody
else…” [White, female, USA] [65]. The relatively young
age for vaccination may encourage some parents to
make the decision on behalf of their daughter: “I figured
now is the best time because it’s a time that I can make
the decision for her and I wanted to make sure she was
protected before there was any chance of her becoming
sexually active” [Mother, USA] [53].
Very few studies examined young women’s views of the
decision-making process [45,47,62]. There was some lim-
ited evidence to suggest young women were willing for
decision-making to be the responsibility of parents and
older adults [47,62]: “I mean… We didn’t take much notice
of the forms, and we handed it to our parents and they
make the choice… It’s like your parents are the boss of you,
sort of. You don’t choose, ‘oh I’m going to get a cervical
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Young women may be disengaged: “It doesn’t matter, I
didn’t really care about it either way” [Young woman, age
13, USA] [45]. Others may prefer greater involvement and
to be better informed about the HPV vaccine and their
parents’ decision: “I did some research (on the net) at the
time my mum said no. So I went in to learn more about
it… She seemed to be thinking at the moment it is rela-
tively new, and she didn’t have much confidence in that I
needed it yet” [Young woman, Australia] [47]. There was
also limited evidence of young women exercising agency
to prevent vaccination: “Well she [my daughter] is just nee-
dle phobic… Even though I signed the consent forms; she
just doesn’t turn up to them. Getting to this age makes it
hard, too, because she just says ‘well it’s my body, my
choice, and I’m not going’ ” [Parent, Australia] [47].
Discussion
Key findings
The studies included in this review illustrate how a young
woman’s access to the HPV vaccine is shaped by decisions
at different levels of the socio-ecological model. This in-
cludes: the policy context; social norms and values, par-
ticularly in relation to sexual activity; the views and
actions of healthcare professionals, and; parental consent.
There is far less qualitative evidence of the role of young
women in this important decision affecting their future
sexual, physical and reproductive health. The stages at
which decisions are made before young women are able
to exercise any agency over whether they receive the vac-
cine are illustrated in Figure 2. Healthcare professionals’
decisions to recommend HPV vaccination, and the re-
quirement for written parental consent, appear to be the
most influential stages at which improvements to uptake
of HPV vaccination programmes could be addressed.
Policy decisions
Some of the most important decisions affecting access to
the HPV vaccine are made at policy level, and relate to
whether the vaccine is incorporated into the healthcare
system, the financial arrangements for accessing the vac-
cine, and the arrangements for its delivery to the target
population. A systematic review examining predominantly
quantitative data from 22 studies (21 of which were con-
ducted in the USA), reported that when cost is a factor in
vaccine access it dominates as a barrier [72]. Similarly, the
data examined for this qualitative systematic review and
evidence synthesis highlight the importance of financial
considerations to healthcare professionals and families
where the costs of the vaccine are not met through a uni-
versal healthcare system. Studies investigating factors
which affected decision-making at the policy level were
underrepresented in the literature. Given the importance
and cost of implementing initiatives such as HPVvaccination programmes, further research to understand
factors that influence policy-level decision making should
be considered.
Healthcare recommendation
In healthcare settings, an important prompt to uptake ap-
peared to be the decision for the healthcare professional
to recommend vaccination. This has been reported in a
systematic review, comprising predominantly quantitative
primary studies, of barriers to HPV vaccination [73] and a
statistical analysis linking HPV vaccine uptake with survey
data from the US-Teen Survey [74]. The qualitative data
also suggest the decision to recommend was influenced by
concerns about safety of the HPV vaccine. However, value
judgements about a young women’s likely sexual activity
were also influential. Universal recommendation of the
HPV vaccine needs to be incorporated into routine prac-
tice to ensure access for all eligible young women. Future
studies could test whether patient reminder systems and
computer prompts that remind healthcare professionals
to recommend HPV vaccine to vaccine eligible young
women increases uptake [75].
Parental consent
The barrier of requiring a healthcare professional’s recom-
mendation to receive the HPV vaccine was largely over-
come in school-based programmes where the policy is to
offer HPV vaccine universally to eligible young women.
However, in this setting the requirement for written par-
ental consent presented the greatest barrier to access.
Healthcare professionals delivering the HPV vaccination
programme could adapt implementation procedures to
reach apparently ‘disengaged’ parents. This could be tested
in existing HPV vaccination programmes by introducing
strategies to introducing home visiting or chasing up con-
sent forms if not returned [61,76].
Young women’s autonomy
Vaccine safety, misperceptions of need based on sexual
activity, and low perceptions of risk of HPV acquisition
have been highlighted as barriers to positive HPV vaccine
decision-making by young women [72]. However, the
findings from this study suggest that young women are
predominantly passive recipients of the HPV vaccine.
Parents generally appeared keen to retain their role in
decision-making on behalf of their daughters, and health-
care professionals appeared to reinforce this role.
Other combinations of decision-making about HPV
vaccine were also identified. Vaccination may be sought
by young women when parental consent has been ac-
tively refused or when a parental consent form has not
been returned. Young women may also exercise their
rights to refuse vaccination when parental consent has
been granted, although there was little evidence for this
Figure 2 Pathways of decision-making in relation to HPV vaccination of young women in high-income countries.
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address gaps in our understanding of this important
process, further qualitative research should examine
young women’s perceptions of, and involvement in,
decision-making about the HPV vaccine. Further, health-
care professionals may require clear guidance and sup-
port in understanding how and when a young woman
might be given the vaccine without parental consent.
Social norms and values
A secondary objective of this review was to gain under-
standing of the factors contributing to inequalities in up-
take of the HPV vaccination programme by ethnicity
previously identified [4,7]. Corresponding with the fin-
dings of other studies [72,73], the importance of social
norms and values, particularly sexual mores, were evident
in the views of healthcare professionals, parents and
young women. The qualitative evidence presented here
suggests that some healthcare professionals avoided con-
versations with parents about the HPV vaccine if they per-
ceived this to be culturally inappropriate. Lower likelihood
of healthcare provider recommendation amongst ethnic
minority parents has also been demonstrated from survey
data of the United States National Immunisation Survey-
Teen [74]. Young women are at risk of not receiving full
levels of protection from the HPV vaccine if parents and
healthcare professionals restrict access to the HPV vaccine,
regardless of her needs and preferences. Development of
strategies for healthcare professionals to overcome barriers
to recommend HPV vaccination universally, regardless of
cultural or religious group, are required.
Mistrust of the motivations of healthcare professionals
in relation to the HPV vaccine was a pertinent issue for
some minority ethnic groups. In the USA, the historicallegacy of the mistreatment of African Americans in the
Tuskegee syphilis experiment [77] (during which the USA
Public Health Service studied the natural progression of
untreated syphillis in rural African American men who
thought they were receiving free health care) may contri-
bute to levels of mistrust in contemporary populations.
However, in other countries and in other populations
there was also evidence of concerns about the safety of
the vaccine by healthcare professionals as well as parents.
Such concerns are exacerbated by negative media cover-
age. For example, in the UK the death of a young woman
on the day she received the HPV vaccination received
widespread media coverage and prompted anxiety in the
wider population [78], despite her death being unrelated
to the vaccine. Such stories reinforce anti-vaccine beliefs
held by some sections of the population. Issues of trust
require clear, accessible, and sometimes culturally appro-
priate, information about the HPV vaccination. Further,
identifying community-engagement strategies to strengthen
relationships between healthcare professionals and the po-
pulations they serve may be beneficial.
Strengths and limitations
A systematic search of multiple databases was undertaken
to identify all the relevant qualitative literature meeting
the predetermined study criteria. Studies were not ex-
cluded on the basis of qualitative research method, or
publication date, or population group. This has resulted in
a comprehensive review capturing a range of perspectives
resulting in a more complete picture in relation to
decision-making for HPV vaccination of young women.
The method of using qualitative synthesis within a socio-
ecological framework enabled facilitators and barriers to
be identified in relation to different stakeholders. This
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at the appropriate level of decision-making, as well as
identifying areas for further research.
Previously applied research methods to synthesis find-
ings of qualitative studies were used to carry out the study
[22,23]. The strengths of a qualitative synthesis include
the possibility to reach conclusions based across common
elements identified in heterogeneous studies. The results
from a synthesis may be more accessible to a wider audi-
ence than if each of the primary studies had to be located
individually. Further, a synthesis can provide a weight of
evidence about particular issues. For example, few primary
studies identified specifically addressed factors affecting
uptake in minority ethnic populations. However, when the
studies were combined more data on this topic was
revealed.
There are some limitations. Studies not published in
English were excluded and the findings reported there-
fore may be subject to English language publication bias.
Although study selection was not limited by study de-
sign, few primary studies incorporating observational
methodology were retrieved. Further, many of the stu-
dies reported views of stakeholders in relation to a hypo-
thetical HPV vaccine. Therefore, primary studies have
reported accounts provided by participants which may
not reflect actual practice.
Thematic synthesis was undertaken by one reviewer
(HF) with discussions held with the second reviewer (SA)
as analysis progressed. The interpretation of the primary
study findings, and consequently a different thematic
framework, may have emerged if an additional reviewer
had undertaken analysis at this stage. The subsequent
exclusion of low- and middle-income countries from the
study limits applicability of the findings within these set-
tings. Further research to understand barriers and faci-
litators to HPV vaccination of young women in low-
and middle-income countries is recommended. Finally,
theoretical frameworks were underutilised in the primary
studies. Of the 41 studies included in this review, only
eight reported using theoretical models in the study
[37,38,41,43,50,60,61,70].
Conclusion
Our study findings show that access to the HPV vaccine
is governed by parental influences, health professional
recommendations, social norms and values, organisa-
tional factors and policy context. As such, interventions
targeted only at young women are likely to be the least
effective approach. Although young women are the main
participants and beneficiaries of the HPV vaccination
programme, their views are underrepresented in the lit-
erature. Future research efforts should develop context
specific, culturally appropriate strategies that increase
equitable access to the HPV vaccine.Additional file
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